Published in
American Society of Hematology, Blood, 2(131), p. 182-190
DOI: 10.1182/blood-2017-09-804641
Links
Tools
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
Journal article published in 2017 by
Nancy L. Bartlett 
,
Bartlett Nl,
Brian A. Costello,
Costello Ba,
Betsy R. LaPlant,
LaPlant Br,
Lim S. Thye,
Stephen M. Ansell,
Ansell Sm,
John G. Kuruvilla,
Craig B. Reeder,
Kuruvilla Jg,
Reeder Cb,
Daniel M. Anderson,
Thye Ls
and other authors.
,
Bartlett Nl,
Brian A. Costello,
Costello Ba,
Betsy R. LaPlant,
LaPlant Br,
Lim S. Thye,
Stephen M. Ansell,
Ansell Sm,
John G. Kuruvilla,
Craig B. Reeder,
Kuruvilla Jg,
Reeder Cb,
Daniel M. Anderson,
Thye Ls
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points Ibrutinib has modest activity in FL with low response rates in rituximab-refractory patients. CARD11 mutations predict for lack of response to ibrutinib.